PANNA

15

Oct, 2017

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women

 

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Clin Infect Dis. 2017; 65(8):1335-1341

Abstract: The use of antiretroviral therapy during pregnancy is important for control of maternal human immunodeficiency virus (HIV) disease and the prevention of perinatal HIV transmission. Physiological changes during pregnancy can reduce antiretroviral exposure. We studied the pharmacokinetics of rilpivirine 25 mg once daily in HIV-1-infected women during late pregnancy.

4

Aug, 2016

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

 

Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.

Published in: Front Pharmacol. 2016; 7:239.

Abstract: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.

Read

31

Jul, 2016

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

 

Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.

Published in: Aids. 2016; 30(12):1999-2001

15

May, 2016

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women

 

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. 2016; 30(8):1239-1244

Abstract: To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.

13

Mar, 2016

First reported use of elvitegravir and cobicistat during pregnancy

 

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. Vol 30. England2016:807-808.

1

Sep, 2015

Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

 

Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.

Published in: Clin Infect Dis. 2015; 61(5):809-816. Epub 2015

Abstract: The use of raltegravir in human immunodeficiency virus (HIV)-infected pregnant women is important in the prevention of mother-to-child HIV transmission, especially in circumstances when a rapid decline of HIV RNA load is warranted or when preferred antiretroviral agents cannot be used. Physiological changes during pregnancy can reduce antiretroviral drug exposure. We studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in HIV-infected pregnant women.

Read

22

Jul, 2015

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women

 

Authors: Colbers A, Best B, Schalkwijk S, et al.

Published in: Clin Infect Dis. 2015; 61(10):1582-1589.

Abstract:To describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)–infected women during pregnancy and post partum.

Read

1

Feb, 2015

Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women

 

Authors: Colbers A, Molto J, Ivanovic J, et al.

Published in: J Antimicrob Chemother. 2015; 70(2):534-542

Abstract: To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum.

Read

1

Jan, 2015

Atazanavir exposure is effective during pregnancy regardless of tenofovir use

 

Authors: Colbers A, Hawkins D, HidalgoTenorio C, et al.

Published inAntivir Ther. 2015; 20(1):57-64

Abstract: We studied the effect of pregnancy on atazanavir pharmacokinetics in the presence and absence of tenofovir.

Read

13

Mar, 2013

The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women

 

Authors: Colbers AP, Hawkins DA, Gingelmaier A, et al.

Published in: Aids. 2013; 27(5):739-748.

Abstract: To describe the pharmacokinetics of tenofovir and emtricitabine in the third trimester of pregnant HIV-infected women and at postpartum.